Dendreon Corp. (DNDN)
-NasdaqGS 3.99 
0.09(2.21%) 20 Jun 06:00|After Hours
:
3.99 0.00 (0.00%) 20 Jun 06:32
| Prev Close: | 4.08 |
|---|
| Open: | 4.10 |
|---|
| Bid: | 3.91 x 500 |
|---|
| Ask: | 4.10 x 100 |
|---|
| 1y Target Est: | 4.34 |
|---|
| Beta: | 2.94 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 3.98 - 4.11 |
|---|
| 52wk Range: | 3.69 - 7.94 |
|---|
| Volume: | 2,358,270 |
|---|
| Avg Vol (3m): | 4,060,400 |
|---|
| Market Cap: | 607.40M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.42 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- An Interview With Elemer Piros: A Strong Year For Biotechs, Looking From The Halfway Pointat Seeking Alpha(Wed 19 Jun)
- Where Is Biotechnology's Next 'Anti-PD-1'?at Seeking Alpha(Tue 18 Jun)
- J&J to Buy Aragon Pharmaceuticals for Cancer Candidateat Bloomberg(Tue 18 Jun)
- Beware the Bullishness on Bristol-Myersat Motley Fool(Sun 16 Jun)
- PropThink: Dendreon Q3 Earnings Preview: Can the Company Overcome the Odds?ACN Newswire(Thu 25 Oct)
- PropThink: Analyst Rating and Trial Enrollment Completion Moving IMUC This WeekACN Newswire(Fri 7 Sep)
- PropThink: Rating Lends Momentum to Oncothyreon Volume; Shares Strong TodayACN Newswire(Sat 25 Aug)
- Equity Briefing: Upgrades and Downgrades for July 31st: ALLT, APC, ARW, CRUS, DNDN, ENS, GPI, HSC, HUM, LOGMACN Newswire(Thu 2 Aug)
- Healthcare Review: Pfizer & Cryolife Gian, Dendreon Slides Big and Has Amarin Bottomed Out?ACN Newswire(Wed 1 Aug)
- Equity Briefing: Upgrades and Downgrades for July 31st: DNDN, DNDN, DOW, DTV, EXC, FB, HCBK, HOLX, LECO, LM, LACN Newswire(Wed 1 Aug)
- Priority Review for Bayer's DrugZacks(Fri 15 Feb)
- Encouraging Prelim Results at DNDNZacks(Wed 9 Jan)
- Dendreon Sells Manufacturing UnitZacks(Fri 28 Dec)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 2.00 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.55 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.42 |
|---|
| Mean Recommendation*: | 3.4 |
|---|
| PEG Ratio (5 yr expected): | -0.03 |
|---|
Business Summary
Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients.
View More